Search results
Showing 3701 to 3750 of 4091 results for patient
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Discontinued Reference number: GID-TA11000
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Discontinued Reference number: GID-TA11264
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development Reference number: GID-MT567 Expected publication date: TBC
In development Reference number: GID-TA11585 Expected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-TA11569 Expected publication date: TBC
In development Reference number: GID-TA11074 Expected publication date: TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Discontinued Reference number: GID-TA10995
Digital technologies for multidisciplinary weight management
In development Reference number: GID-HTE10077 Expected publication date: TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development Reference number: GID-TA10858 Expected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
In development Reference number: GID-TA11146 Expected publication date: TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041
Discontinued Reference number: GID-TA10996
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Discontinued Reference number: GID-TA11109
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
Discontinued Reference number: GID-TA10154
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Discontinued Reference number: GID-TA11005
In development Reference number: GID-TA11163 Expected publication date: TBC
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
Discontinued Reference number: GID-MT517
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244
Discontinued Reference number: GID-TA11318
In development Reference number: GID-TA11214 Expected publication date: TBC
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Discontinued Reference number: GID-TA11007
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
In development Reference number: GID-TA11528 Expected publication date: TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development Reference number: GID-TA11086 Expected publication date: TBC
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
In development Reference number: GID-TA11008 Expected publication date: TBC
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
Discontinued Reference number: GID-TAG387
Seven digital platforms supporting at home cardiac rehab given conditional recommendations
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.
NICE's prioritisation process explained – what healthtech developers need to know
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.
Newly recommended CBT therapies could help children and young people deal with anxiety
NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS
Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.
New AI tools could help save lives by spotting warning signs of bowel cancer earlier
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.